Miltenyi Biotec introduces the largest portfolio of recombinant antibodies optimized for flow cytometry – REAfinity™ Antibodies
BERGISCH GLADBACH, December 8, 2016 – Miltenyi Biotec has expanded its antibody portfolio and now offers more than 500 new recombinantly engineered antibodies – the REAfinity™ Antibodies optimized for flow cytometry. These antibodies display considerable advantages over conventional monoclonal antibodies and their introduction thereby contributes significantly to the standardization of antibodies in research.
Recently, there has been an intense discussion on the reproducibility of experiments in the scientific community. Being part of the scientific community, Miltenyi Biotec takes this topic very seriously. With the recombinantly engineered REAfinity™ Antibodies, optimized for flow cytometry, the company makes a significant contribution to improving quality and consistency of experimental results. The strictly standardized antibody production process starting from a defined DNA sequence ensures high purity and lot-to-lot consistency. In addition, these recombinant antibodies do not display any undesired mixtures of heavy and light immunoglobulin chains, which is often the case with conventional monoclonal antibodies. These advantages make REAfinity™ Antibodies the ideal tool for improving experimental reproducibility.
“Our REAfinity™ Antibodies are the new generation of flow cytometry antibodies,” explains Dr. Kalpana Singh, product manager for the MACS® Antibody portfolio at Miltenyi Biotec. “For researchers this means easy access to the benefits of recombinant antibody technology. Until now, the advantages of this technology were not readily available to every scientist and only researchers in pharma companies could benefit from this technology.
Another important topic to us is the validation of antibodies, this is why we are in constant dialog with scientists across the globe to help raising the standards in antibody validation.”
Optimized for flow cytometry by eliminating background signaling
Certain site-specific mutations are introduced into REAfinity™ Antibodies to eliminate non-specific binding of antibodies to Fc receptors, thereby avoiding background signals. The result: specific and accurate detection of target antigens and confident analysis, which leads to savings in time and increased quality of data.
REAfinity™ Antibodies complement Miltenyi Biotec’s comprehensive MACS® Antibodies Portfolio, which already includes a broad spectrum of high-quality fluorochrome-conjugated antibodies, functional antibodies for cell culture, and proprietary fluorochromes.
See how our REAfinity™ Antibodies are optimized and validated for flow cytometry experiments:
About Miltenyi Biotec
Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. The company’s innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Miltenyi Biotec’s technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. Their more than 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In their commitment to the scientific community, Miltenyi Biotec also offers comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 1,700 employees in 25 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.
Miltenyi Biotec Media Contact
Dr. Anja Kohmann
Tel.: (02204) 83 06-6672
Download media release (PDF)
back to all news